Biogen Inc.

225 Binney Street
02142 Cambridge
US

Contact WebSite

Article

Biogen Acquires Human Immunology Biosciences
23.05.2024 • News

Biogen Acquires Human Immunology Biosciences

Biogen and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), have entered into a definitive agreement. Biogen has agreed to acquire HI-Bio for $1.15 billion (€1.06 billion) upfront and up to $650 million (€600.5 million) in potential milestone payments.